HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of a novel orally administered calpain inhibitor SNJ-1945 on immunomodulation and neurodegeneration in a murine model of multiple sclerosis.

Abstract
Multiple sclerosis (MS) pathology is marked by the massive infiltration of myelin-specific T cells into the CNS. Hallmarks of T helper (Th) cells during active disease are pro-inflammatory Th1/Th17 cells that predominate over immunoregulatory Th2/Treg cells. Neurodegeneration, a major factor in progressive MS, is often overlooked when considering drug prescription. Here, we show that oral dosing with SNJ-1945, a novel water-soluble calpain inhibitor, reduces experimental autoimmune encephalomyelitis clinical scores in vivo and has a two pronged effect via anti-inflammation and protection against neurodegeneration. We also show that SNJ-1945 treatment down-regulates Th1/Th17 inflammatory responses, and promotes regulatory T cells (Tregs) and myeloid-derived suppressor cells in vivo, which are known to have the capacity to suppress helper as well as cytotoxic T cell functions. Through analysis of spinal cord samples, we show a reduction in calpain expression, decreased infiltration of inflammatory cells, and signs of inhibition of neurodegeneration. We also show a marked reduction in neuronal cell death in spinal cord (SC) sections. These results suggest that calpain inhibition attenuates experimental autoimmune encephalomyelitis pathology by reducing both inflammation and neurodegeneration, and could be used in clinical settings to augment the efficacy of standard immunomodulatory agents used to treat MS. Multiple sclerosis (MS) pathology is marked by inflammation and infiltration of myelin-specific T cells into the central nervous system. Inflammation leads to neurodegeneration in progressive MS which also leads to epitope spreading, feedback looping to more inflammation. Calpain can play a role in both arms of the disease. Here, oral dosing with SNJ-1945, a novel water-soluble calpain inhibitor, reduces experimental autoimmune encephalomyelitis clinical scores in vivo and has a two-pronged effect via anti-inflammation and protection against neurodegeneration.
AuthorsNicole Trager, Amena Smith, Gerald Wallace Iv, Mitsuyoshi Azuma, Jun Inoue, Craig Beeson, Azizul Haque, Naren L Banik
JournalJournal of neurochemistry (J Neurochem) Vol. 130 Issue 2 Pg. 268-79 (Jul 2014) ISSN: 1471-4159 [Electronic] England
PMID24447070 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2014 International Society for Neurochemistry.
Chemical References
  • ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester
  • Carbamates
  • Cysteine Proteinase Inhibitors
  • Calpain
Topics
  • Animals
  • Blotting, Western
  • Calpain (antagonists & inhibitors)
  • Carbamates (pharmacology, therapeutic use)
  • Cell Proliferation (drug effects)
  • Cell Separation
  • Cysteine Proteinase Inhibitors (pharmacology, therapeutic use)
  • Disease Progression
  • Encephalomyelitis, Autoimmune, Experimental (drug therapy, pathology)
  • Enzyme-Linked Immunosorbent Assay
  • Flow Cytometry
  • Immunohistochemistry
  • Immunomodulation (drug effects)
  • In Situ Nick-End Labeling
  • Male
  • Mice
  • Monocytes (drug effects)
  • Multiple Sclerosis (drug therapy, pathology)
  • Nerve Degeneration (drug therapy, pathology)
  • Real-Time Polymerase Chain Reaction
  • T-Lymphocytes, Helper-Inducer (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: